When was Cytotheryx founded?

Cytotheryx was founded in 2018 and raised its 1st funding round 8 years after it was founded.

Where is Cytotheryx located?

Cytotheryx is headquartered in Rochester, United States.

How many employees does Cytotheryx have?

As of Aug 31, 2026, the latest employee count at Cytotheryx is 16.

Is Cytotheryx a funded company?

Cytotheryx is a funded company, having raised a total of $60M across 2 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Jan 12, 2026.

When was the latest funding round of Cytotheryx?

Cytotheryx's latest funding was a $***** Series A round on Jan 12, 2026, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $1.3B in funding in 2026 to date.

Where does Cytotheryx rank among its competitors?

Cytotheryx ranks 7th amongst 114 active competitors, of which 30 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Cellply, which secured $8.36M in May, 2026.

Who are the top competitors of Cytotheryx?

Cytotheryx's top competitors include Bit.bio, Cellply and Kiyatec. Among them, Cellply secured the most recent funding round in May, 2026.

Cytotheryx - 2026 Company Profile, Funding & Competitors

Cytotheryx is a series A company based in Rochester (United States), founded in 2018. It operates as a Developer of human hepatocytes for research and clinical applications. Cytotheryx has raised $60M in funding from Ouroboros Family Founders Fund I. The company has 114 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like Bit.bio, Cellply and Kiyatec.

Company Details

Developer of human hepatocytes (HHC) for research and clinical applications. The company develops HHC for toxicology study, hepatitis research, and allotransplants.

Website: cytotheryx.com
Email ID: *****@cytotheryx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Rochester, United States

Stage

Series A

Total Funding

$60M in 2 rounds

Latest Funding Round

Series A, Jan 12, 2026, $*****

Investors

Ouroboros Family Founders Fund I & 2 more

Ranked

7^th among 114 active competitors

Employee Count

16 as on Aug 31, 2026

Similar Companies

Bit.bio & 153 more

View Cytotheryx's full profile

Cytotheryx has raised a total funding of $60M over 2 rounds. Its first funding round was on Jan 12, 2026. Cytotheryx has 3 institutional investors.

Here is the list of recent funding rounds of Cytotheryx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 12, 2026	3430440	Series A	6824481	5721384	1772304	4620673
Jan 12, 2026	2113247	Conventional Debt	7665029	6754779	9648485	3215576

Access funding benchmarks and valuations. Sign up today!

View details of Cytotheryx's funding rounds and investors

Cytotheryx's employee count trend

Cytotheryx has 16 employees as of Aug 26. Here is Cytotheryx's employee count trend over the years:

Uncover Cytotheryx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cytotheryx include Bit.bio, Cellply and Kiyatec. Here is the list of Top 10 competitors of Cytotheryx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bit.bio 2016, Cambridge (United Kingdom), Series C	Manufacturer of programmed human cells for research and drug discovery	$266M	M&G, Foresite Capital & 53 others	67/100
2nd	Cellply 2013, Bologna (Italy), Series B	Developer of in-vitro diagnostic products for the detection of cancer	$16.4M	LIFTT, Indaco Venture Partners & 15 others	60/100
3rd	Kiyatec 2005, Pendleton (United States), Series C	Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment	$29.5M	VentureSouth, MBD Biotech & 13 others	55/100
4th	CytoTronics 2015, Boston (United States), Series A	Developer of cell-based assays for drug discovery	$22.8M	Anzu Partners, BoxOne Ventures & 1 others	55/100
5th	Saguaro 2020, Quebec City (Canada), Seed	Developer of 3D cell culture products for drug discovery	$4.1M	Anges Quebec, AQC Capital & 3 others	50/100
6th	Pelago Bioscience 2013, Solna (Sweden), Seed	Assay services for use in the determination and quantification of drug-target interactions	-	Impilo, Europa & 1 others	48/100
7th	Cytotheryx 2018, Rochester (United States), Series A	Developer of human hepatocytes for research and clinical applications	$60M	Hill Capital & 2 others	47/100
8th	StemBioSys 2010, San Antonio (United States), Series A	Cell culture technology company advancing regenerative medicine and drug discovery	$14.5M	JLABS, Targeted Technology & 3 others	45/100
9th	SK Plasma 1970, Seongnam-si (South Korea), Funding Raised	Manufactures plasma derivatives	-	Korea Investment Holdings	45/100
10th	Nanocrine 2018, Frederick (United States), Seed	Provider of a cell analysis and drug design tool for researchers	$300K	TEDCO, America’s Seed Fund	43/100